Shares in LLY are up 16% year-to-date and analysts have a cautiously optimistic Moderate Buy consensus on the stock's outlook. That's alongside a $173 average analyst price target (13% upside potential). "We see Lilly as a best-in-class story but have remained Neutral on the stock given the premium multiple at which it has been trading" commented Mizuho Securities analyst Vamil Divan on August 3, after the company delivered an 'admittedly messy 2Q20.'